These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17314999)

  • 21. Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy.
    Pedersen OL; Mancia G; Pickering T; Høegholm A; Julius S; Kjeldsen SE; Nielsen ES; Refsgaard J; Weber M;
    J Hypertens; 2007 Mar; 25(3):707-12. PubMed ID: 17278988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
    Brachmann J; Ansari A; Mahla G; Handrock R; Klebs S
    Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
    Yamashita K; Kondo T; Muramatsu T; Matsushita K; Nagahiro T; Maeda K; Shintani S; Murohara T
    Am J Cardiol; 2013 Dec; 112(11):1750-6. PubMed ID: 24035165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
    Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
    Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
    Fogari R; Derosa G; Ferrari I; Corradi L; Zoppi A; Lazzari P; Santoro T; Preti P; Mugellini A
    Am J Hypertens; 2008 Sep; 21(9):1034-9. PubMed ID: 18566593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy.
    Kondrack R; Mohiuddin S
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1125-34. PubMed ID: 19689218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks].
    Praxis (Bern 1994); 2004 Oct; 93(42):1748. PubMed ID: 15529964
    [No Abstract]   [Full Text] [Related]  

  • 29. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
    Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
    Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial.
    Kloner RA; Neutel J; Roth EM; Weiss R; Weinberger MH; Thakker KM; Schwartz B; Shi H; Gregg AM;
    Ann Pharmacother; 2008 Nov; 42(11):1552-62. PubMed ID: 18827176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
    Hollenberg NK; Parving HH; Viberti G; Remuzzi G; Ritter S; Zelenkofske S; Kandra A; Daley WL; Rocha R
    J Hypertens; 2007 Sep; 25(9):1921-6. PubMed ID: 17762658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
    Hermida RC; Ayala DE; Khder Y; Calvo C
    Clin Ther; 2008 Jan; 30(1):108-20. PubMed ID: 18343247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
    J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study.
    Muramatsu T; Matsushita K; Yamashita K; Kondo T; Maeda K; Shintani S; Ichimiya S; Ohno M; Sone T; Ikeda N; Watarai M; Murohara T;
    Hypertension; 2012 Mar; 59(3):580-6. PubMed ID: 22232134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
    Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
    Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [VALUE study underscores the importance of reaching goal blood pressure values for minimization of cardiovascular risks].
    Praxis (Bern 1994); 2004 Oct; 93(44):1836. PubMed ID: 15559910
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.
    Epstein M; Hollenberg NK
    Am J Hypertens; 2004 Jul; 17(7):638-9; author reply 639-40. PubMed ID: 15233985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.